



Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

We continuously enhance the capabilities for innovation, service, integration and international operations to efficiently operate, manage and invest in outstanding enterprises in the industry so that we can become a leading provider of healthcare products and services.

02
05
06
12
51
52
70
72
82

90
96
97
98
100
102
105
241

u d

u

u d

d d u d
d d
d d
d d
d d u
d d

Executive Directors

u 陳啟宇 (Chairman)

姚方 (Co-Chairman)

u 吳以芳

(President and Chief Executive Officer)

Non-executive Directors

u 汪群斌

王燦

u 沐海寧

u 張學慶

u u 郭廣昌

康嵐

Independent Non-executive Directors

u 曹惠民

江憲

u 黃天祐

u 韋少琨

任倩 (Chairman)

曹根興

u 管一民

u 李春

董曉嫻

u 盧綺霞

u 陳啟宇

u 盧綺霞

u 陳啟宇 (Chairman)

姚方

u 吳以芳

u 汪群斌

u 韋少琨

u u 郭廣昌

u 曹惠民 (Chairman)

江憲

王燦

江憲 (Chairman)

u 曹惠民

u 沐海寧

康嵐

u 陳啟宇

u 黃天祐 (Chairman)

u 曹惠民

江憲

u 陳啟宇

u 沐海寧

康嵐

王燦

u u d

u d d

u d

d d u

d

u

u u u d d

d d d

u u u d

d

d

d

u d
u u d
u u d
u d

d
u d

u


05




Dear Shareholders,

In 2018, amidst the situation that was full of challenges and uncertainties in the economies of the world and the PRC, there was ongoing further reform of the medical system in the PRC. The pharmaceutical manufacturing industry grew at a steady pace, while the research of innovative drugs entered a period of rapid development, and medical devices and medical diagnosis benefited from the policies with opportunities for rapid development. With a strong demand for healthcare services and the gradual adjustment in the industry structure, the layout of healthcare service resources became more reasonable. During the Reporting Period, the Group adhered to its business philosophy of "Innovation for Good Health", focused on its core pharmaceutical and healthcare businesses, continued to develop product innovation and improve management as well as international development, actively promoted the strategies of organic growth, external expansion and integrated development, thereby maintaining the balanced growth of its principal businesses.

Chairman





11

[illegible]

U d U d

d

U d

&

&

U d d U U U d
U U U d U U U U U U U U U U U
U U U U U U U U U U U U U U U U U
d U U d U d U d U U U U U U U U U U U

U d U U U d du d U d U d U d
du U U U d U d U d U d U d U d U d
U d d U d U d U d U d U d U d U d U d

U d d U U d U U d U d

U d d U d U U d

du d U d U d U d U d U d U d U d U d
U U d U d U d U d U d U d U d U d U d U d
U d U d U d U d U d U d U d U d U d U d

d U d U d U d U d U d U d U d U d U

u d

d u d d u u d u

d
d

[illegible]

u d d

$\frac{d}{dt} \left(\frac{1}{r^2} \right) = -\frac{2}{r^3} \frac{dr}{dt}$

[illegible]


U U d d U U

This image is a highly complex, abstract black and white pattern. It consists of a dense, irregular arrangement of small, dark, irregular shapes and lines on a white background. The overall effect is that of a stylized map, a data visualization, or a complex network diagram. The shapes are scattered across the entire frame, with some areas appearing more densely populated than others. The pattern is non-repeating and lacks a clear, discernible structure, suggesting a random or semi-random distribution of elements.


[illegible]

Note 2: u d d

[illegible]



Pharmaceutical Manufacturing and R&D



(Note 1)

Diagram illustrating the eight notes of a major scale on a piano keyboard:

- (Note 1) C (white key)
- (Note 2) D (black key)
- (Note 3) E (white key)
- (Note 4) F (black key)
- (Note 5) G (white key)
- (Note 6) A (black key)
- (Note 7) B (white key)
- (Note 8) C (white key)

20 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

[illegible]

Note 1:

Note 2:

Note 3:

Note 4:

Note 5

Note 6:

(Note 5)

Note 5:

[illegible]

[illegible]

A 10x10 grid of 100 cells, each containing a single character from the set {u, d}. The characters are distributed in a seemingly random pattern across the grid.

A 10x10 grid of 100 cells, each containing either the letter 'u' or 'd'. The letters are distributed in a seemingly random pattern across the grid.

Environment, Health and Safety

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The distribution is random, with approximately 45 'u's and 55 'd's.

談家楨生命科學獎

談家楨生命科學獎

責任雲 指數

A. Analysis on Principal Operations

Analysis of Changes in Relevant Items of Income Statement and Statement of Cash Flows

u

[illegible]

U d

u u d u u d
u d u u d u u

(1) Principal Operations by Segments, Products and Geographical Locations

u

u
u u d
(Note 1)

d d d d
d

Note 1:

u d u d u u u d u d u d
u d u d u d u d u d u d
u u d u d u d u d u

(Note 1)

The diagram illustrates the movement of a particle in a fluid, showing its path and the forces acting on it. The particle is represented by a small black dot. The fluid is represented by a light blue background. The particle's path is indicated by a series of dots and lines. The labels 'du' and 'u' are placed at various points along the path, indicating the direction and magnitude of the forces. The notes (Note 2) through (Note 7) provide additional information about the particle's behavior at different stages of its movement.

(Note 2)

(Note 3)

(Note 4)

(Note 5)

(Note 6)

(Note 7)

(Note 8)

Vote 1:

Vote 2:

Vote 3:

d

[illegible]

u du u d d du d u
 du du u u u u u u
 u u d u u u d d u

Note 6:

[illegible]

U U U U U U U U U U U U

u

u d

u

d	du	d
	u d	
	u du	
	d	
d	du	u d
	u d	
	d d	
d	du	u d
	u	d d
	d	

B. Description on the non-principal business leading to significant changes in profit

u d

C. Assets and liabilities analysis

u

[illegible]

U d

d u d u d u u



u u d
u u
d u
u u

Note: d u d u d u

Disposal of Subsidiaries in 2018

u u d u u d d

u u d u d u

d u u u d u u

d u d u d u u

u d u d u u

u 劉海泉 u u u d u u

d u u u d d u

u d u d u d u

天誠藥業 u u d d u d u

d u d d u d u

u d u d u d u

u 葉雪強 u 王立文 d u u 胡學科 u u

d u d u d u d u u

U d

d u d u du d u
u


u u d u u
u u u u

E. Core Competence Analysis

d u d u u u d u u u d
d d d d u u d u u u d
du u du u d u d du
d d d du u d d
u u u d u d
dd u d u d d d d
d u u du u d u d d
d u u du u d u d
d u u d u d
d u u u d d d
d u u d d d d

F. Employees and Remuneration Policies


d u d u d u d u




Pharmaceutical Manufacturing and R&D



Healthcare Services



Medical Devices and Medical Diagnosis



Pharmaceutical Distribution and Retail



Financing



Investment Projects under Construction

u

I. Risks in relation to industry policies and system reforms

I. Risks in relation to industry policies and system reforms

II. Market risks

8. Shanghai Henlius Share Option Incentive Scheme

9. Proposed spin-off and overseas listing of Shanghai Henlius

%

u

● ● ● ●

d u d

u u u

d

d
 d d d u
 u

(Note 1)

(Note 2)

(Note 2)

(Note 2)

u u u d

d d

Note 1: d u d d d u du d

Note 2: 

Response	Percentage
Yes	85%
No	15%

業股東派發股息代扣代繳企業所得稅有關問題的通知》

《關於中國居民企業向境外 股非居民企

業股東派發股息代扣代繳企業所得稅有關問題的通知》

《關於國稅發 號文件廢止後有關個人所得稅徵管問題的通知》



■ ■ ■ u ■

u 陳啟宇 (Chairman)
姚方 (Co-Chairman)
u 吳以芳 (President and Chief Executive Officer)

u 汪群斌
王燦
u 沐海寧
u 張學慶

u 曹惠民
江憲
u 黃天祐
u 韋少琨


■ u u ■ u ■ u ■ u
■ u u ■ u ■ u

■ ■ u

任倩
u 曹根興
管一民

u ■ ■ ■ ■ ■
■ u ■ u ■ u ■ u

u ■ u ■ u



u u d u u d d d u
 u d u u d u u d
 u d u d u d u d

d d d d u u

u d d u u d u d
 d u d u d u d
 d u u d u d

u d d d u u d u
 u d d d u d u d
 u d d u u u d d

u
 u

u
 u

Note:

64 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

d	u	d	du	d d	u	d
		d d	u		u	du
u	u	d	u	d	u d	

		u	d
u	u d	u	
d u d		u	u
(Note 1)	d u d		
	u	u	
	d u d		

(Note 2)

d		d	
u u u			

(Note 3) (Note 3)

u	(Note 4)
u d u d	
d d	u
u d u d	
d u	
d d	
u d	

Notes:

u	d	u d	u d	u	d	u	u
u	d	u	d		u d	d d	u
d	u		d d		u	u	
d	u		d d u	u	u d	u	d u
u d		d		u			

d d u u d (note)
 d u d

U d u U (note)

Note:

本公司於2018年12月31日止年度，根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.06條，披露有關本公司之財務資料。

本公司之財務資料，乃根據本公司之會計政策及估計，並經本公司之核數師審核。本公司之財務資料，乃根據本公司之會計政策及估計，並經本公司之核數師審核。

本公司之財務資料，乃根據本公司之會計政策及估計，並經本公司之核數師審核。

外上市外資股的批覆》
 《關於核准上海復星醫藥集團股份有限公司增發境
 本公司於2018年12月31日止年度，根據《香港聯合交易所有限公司證券上市規則》（「上市規則」）第13.06條，披露有關本公司之財務資料。

本公司之財務資料，乃根據本公司之會計政策及估計，並經本公司之核數師審核。

議事規則

監事會

(《上海復星醫藥(集團)股份有限公司第二期限制性股票激勵計劃(修訂稿)》)

d


d

u

d d

Entity	Percentage
Current government	85%
Opposition	15%





Under the leadership of the Group's senior management, the Group's research and development department is responsible for the following work:

- understanding and mastering the overall operations of the Group, the international and domestic market trends and the
- researching and advising on the short-term, medium-term and long-term development strategies of the Group and major
- reviewing and approving research reports on development strategy.

The Group's research and development department is responsible for the following work:

The Group's research and development department is responsible for the following work:

d d u

d d d

d d d

u

u

u u
u

u

u

u

u

u

Notes:

A large, abstract, black and white graphic that resembles a stylized, fragmented map or a complex network of interconnected lines and shapes. The graphic is composed of numerous small, irregular black shapes and lines scattered across a white background, creating a sense of depth and complexity. The overall form is roughly rectangular but with many protrusions and indentations, suggesting a geographical outline or a conceptual diagram. The black elements are of varying sizes and orientations, some appearing as solid shapes and others as thin lines, contributing to a textured, almost pixelated appearance. The distribution of these elements is uneven, with some areas being more densely populated than others, giving the impression of a map where certain regions are more prominent or detailed than others. The overall effect is one of a highly detailed, yet abstract, representation of a space or a system.

U d d d d U

u d u d d d u u u

u u

u d

d

dd

d

d

d

du

u

d

du

d

d

d

d

d

d

u

d

u

u

u

d

u

d

d

d

u

Note:

d

u

u

d

d

u

u

d

d

u

u

u

d

dd

u

d

d

u

d

u

d

u

d

d

d

du

d

u

u

dd

d

d

d

d

d

u

d

d

d

d

d

d

d

u

d

d

u

d

d

u

d

d

u

d

u

u

u

d

d

d

u

d

d

u

u

u

d

d

d

d

d

d

d

u

d

u

d

d

u

d

d

d

u

d

u

d

u

u

d

d

d

u

d

d

u

u

d

u

d

u

d

d

d

u

u

d

陳啟宇

u

d

d

d

u

d

d

d

u

u

d

d

d

d

u

d

d

d

北京三元食品股份有限公司

d

u

d

d

d

d

d

u

d

迪安診斷技術集團股份有限公司

d

u

d

汪群斌

u

d

u

u

d

d

u

u

u

u

d

d

u

u

d

u

d

d

u

u

河南羚銳製藥股份有限公司

d

d

d

u

u

d

上海豫園旅

游商城股份有限公司

d

d

u

d

d

復旦大學

u

王燦

d

d

u

u

u

d

d

d

u

u

d

d

d

u

d

u

u

u

d

d

d

d

d

d

u

u

d

d

u

d

d

u

u

u

d

d

d

d

d

d

金蝶軟件 中國 有限公司

d

d

u

u

u

d

d

d

d

u

d

u

u

d

上海實業發展股份有限公司

上海瀚訊信息技術股份有限

上海百聯集團股份有限公司

上海財經大學

上海第一醫藥股份有限公司

上海市聯合律師事務

華東

上海司法學校

復旦大學

復旦大學

黃天祐

韋少琨

郭廣昌

康嵐

任倩

■ 上海市第一百貨股份有限公司
集團股份有限公司 ■

- 上海百聯

● 中國華源集團有限公司

● 上海中洲會計師事務所有限公司

● 上海華鑫股份有限公司

上海財經大學

曹根興

● 大華 (

U

d

管一民

d

d

u


u

u

u

d

U d





Ernst & Young

安永會計師事務所
香港中環添美道1號
中信大廈22樓

Tel 電話: +852 2846 9888
Fax 傳真: +
ey.com

(Established in the People's Republic of China with limited liability)



(Established in the People's Republic of China with limited liability)

(Established in the People's Republic of China with limited liability)

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, including the risks of non-detection of fraud, and design, implement and perform audit procedures that are appropriate in the circumstances to address the assessed risks of material misstatement, whether due to fraud or error, and obtain sufficient appropriate audit evidence to support the conclusions reached thereon, and to form an opinion on the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not to express an opinion on the effectiveness of internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether there is a material uncertainty related to the directors' ability to continue to adopt the going concern basis of accounting for the foreseeable future, and, if so, disclose the nature of the material uncertainty and, where applicable, the auditor's responsibilities in relation to the material uncertainty.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether they are fair and balanced in all material aspects.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to support the conclusions reached thereon, and to form an opinion on the consolidated financial statements.

&

Certified Public Accountants

dd

Notes

dd u

d

dd

d

u

u

u d u d

u d

[illegible]

	Notes		
d			
d			
u			
u			
u			

Director

Director

Annual Report 2018 101

d d

Notes

d u

d
d

u

d u

d d

d

d u

d

d u
u u

d
d
d
d

u d

d d
d d
d d

u u
u u

u

d d

d

u

u u

u

d

d

d d
d d
d

d u
u

d d

d
d

	Notes	

dd

Notes

d

d

d

d

u

d

u

d

d

d

d

d

d

d

d

U

d

4

d

u

d

u

●

u

Annual Report 2018 105

u

u d

u d

重慶藥友製藥有限責任公司

江蘇萬邦生化醫藥集團有限責任公司

u u d

桂林南藥股份有限公司

上海復星長征醫學科學有限公司

上海復星醫藥產業發展有限公司

U U

錦州奧鴻藥業有限責任公司

U
重慶醫藥工業研究院有限責任公司

岳陽廣濟醫院有限公司

亞能生物技術 深圳 有限公司

大連雅立峰生物製藥有限公司

U			U	d			U	d		
U			d				U	U	d	d
湖北新生源生物工程有限公司			d				d			
d	d		d							
美中互利醫療有限公司										
		U		d			U	U	d	d
瀋陽紅旗製藥有限公司			d				d			
U		安徽濟民腫瘤醫院								
			d							
U		U		d						
宿遷市鐘吾醫院有限責任公司			d							
		d					U	U	d	
							d	d		
U			U		d		U	U	d	d
湖南洞庭藥業股份有限公司			d				d			
				d						
佛山市禪城區中心醫院有限公司			d							
U	U		U		d		U	U	d	d
蘇州二葉製藥有限公司			d				d			
U	U		U		d	U	U	d	d	
江蘇黃河藥業股份有限公司			d				d			

[illegible]

u d

u d

u d

/

d d
d d

u d

d d

u d

u

u d

u

u d

u

u d

u d

u

31 December 2018



A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The letters are distributed in a seemingly random pattern across the grid.

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The letters are distributed across the grid in a seemingly random pattern.

31 December 2018

U d d d d

Financial assets at amortised cost (debt instruments)

- The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

Financial

[illegible]

Financial assets at fair value through profit or loss (Continued)

Initial recognition and measurement

Subsequent measurement

u u u d d

Financial assets at fair value through profit or loss

[illegible]

[illegible]

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The letters are distributed in a seemingly random pattern across the grid.

A scatter plot showing the relationship between the number of children in a household (x-axis) and the number of children in a neighborhood (y-axis). The x-axis ranges from 0 to 10, and the y-axis ranges from 0 to 10. Data points are represented by 'u' for under 10 and 'd' for 10 or more. The plot shows a positive correlation, with many points at (0,0) and (1,1), and fewer points at higher values.

The image consists of a large rectangular area filled with a sparse distribution of small black squares. These squares are arranged in a way that suggests a larger, faint shape, possibly a stylized letter 'E' or a comb-like structure. The squares are more densely packed along certain horizontal and vertical axes, creating a sense of depth and form against the white background.

Financial liabilities at fair value through profit or loss (policies under HKFRS 9 applicable from 1 January 2018)

1. 2019年1-6月，公司实现营业收入1,234,567.89元，较上年同期增长12.34%；实现净利润123,456.78元，较上年同期增长15.67%。

2. 报告期内，公司主营业务毛利率为45.67%，较上年同期提高2.34个百分点，主要系公司通过优化产品结构，提高了高毛利产品的销售占比。

3. 截至报告期末，公司总资产为5,678,901.23元，较年初增加123,456.78元；净资产为3,456,789.01元，较年初增加67,890.12元。

4. 报告期内，公司经营活动产生的现金流量净额为98,765.43元，较上年同期增加12,345.67元，主要系公司加强了应收账款的回收力度。

5. 报告期内，公司不存在重大诉讼、仲裁事项，也不存在其他可能对公司财务状况和经营成果产生重大影响的或有事项。

6. 报告期内，公司严格按照《公司法》、《证券法》及中国证监会的相关规定，规范运作，不存在违法违规行为。

7. 报告期内，公司控股股东、实际控制人不存在占用公司资金、违规担保等行为。

8. 报告期内，公司不存在为他人提供担保的情况。

9. 报告期内，公司不存在募集资金使用情况。

10. 报告期内，公司不存在关联交易情况。

11. 报告期内，公司不存在股权激励计划。

12. 报告期内，公司不存在其他需要披露的重大事项。

Revenue from contracts with customers

[illegible]

Revenue from contracts with customers (Continued)

(a) *Sale of industrial products*

u	du	du	d	
u	d	du	du	

(b) *Healthcare services, technology transfer services and consigned processing services*

u	d		d	d
	d		d	u
u	d		u	d d d

(c) *Rendering of technical consultancy services and maintenance services*

u	d		u	d		d
u	u	u	d	u	d d	u

Revenue from other sources

d

Other income

	d		u	u		d		
d u	d u u			d		u		d
		u						
d d	d		d				d	
	d		d d d		u	d	u	d d d
u d								
u	d					u	d	u
u d								
	d			d	d		d	u
d d	u					d	u u	d
			d	d				
	d		u d			d		u
			d d d					u d
	u d							
d		u	u			d		d u
	d u u		d				u	
	d							
d d d		d				d		

1. 2019年，公司实现营业收入1,234,567.89元，较上年同期增长12.34%。其中，主营业务收入1,123,456.78元，较上年同期增长11.23%；其他业务收入111,111.11元，较上年同期增长13.45%。

2. 2019年，公司实现利润总额156,789.01元，较上年同期增长8.76%。其中，营业利润145,678.90元，较上年同期增长9.12%；营业外收入11,110.11元，较上年同期增长7.89%。

3. 2019年，公司实现归属于上市公司股东的净利润123,456.78元，较上年同期增长7.65%。其中，基本每股收益0.12元，较上年同期增长6.54%；稀释每股收益0.11元，较上年同期增长5.43%。

4. 2019年，公司经营活动产生的现金流量净额98,765.43元，较上年同期增长4.56%。其中，销售商品、提供劳务收到的现金1,345,678.90元，较上年同期增长10.12%；购买商品、接受劳务支付的现金1,234,567.89元，较上年同期增长9.87%。

5. 2019年，公司研发投入15,678.90元，较上年同期增长15.67%。其中，研发费用14,567.89元，较上年同期增长14.56%；研发费用占营业收入比例为1.23%，较上年同期提高0.01个百分点。

6. 2019年，公司资产总额1,234,567.89元，较上年同期增长5.67%。其中，流动资产1,123,456.78元，较上年同期增长5.43%；非流动资产111,111.11元，较上年同期增长6.12%。

7. 2019年，公司负债总额567,890.12元，较上年同期增长3.45%。其中，流动负债545,678.90元，较上年同期增长3.21%；非流动负债22,211.22元，较上年同期增长4.12%。

8. 2019年，公司所有者权益总额666,677.77元，较上年同期增长6.78%。其中，实收资本345,678.90元，较上年同期增长0.12%；资本公积123,456.78元，较上年同期增长0.23%；盈余公积234,567.89元，较上年同期增长1.12%。

9. 2019年，公司总资产周转率1.23次/年，较上年同期提高0.01次/年；净资产收益率12.34%，较上年同期提高0.12个百分点。

10. 2019年，公司加权平均净资产收益率11.23%，较上年同期提高0.11个百分点。

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The letters are distributed in a seemingly random pattern across the grid.

Impairment of non-financial assets (other than goodwill)

Business combinations and goodwill

A 10x10 grid of 100 cells, each containing either the letter 'u' or 'd'. The letters are distributed across the grid in a pattern that is not uniform, with 'u' appearing more frequently than 'd'.

Impairment of available-for-sale investments

u u d u d d d u d u d

Net realisable value of inventories

Useful lives of property, plant and equipment

[illegible]

Useful lives of intangible assets (other than goodwill)

u d d u u u d u u d u
u u u u u u d u d

Deferred tax assets

d d d u d d d u u d d d
u u d d d u u d d d u u d u d d u
d d d u d d d d u
u d u u u u d d d u
d d u u u d d d u

Development costs

d d u d u d d u
d u u u d u u

[illegible]

(a) Revenue from external customers

Diagram illustrating the structure of a nucleon (proton or neutron) composed of three quarks (u and d) and a central blue square representing a gluon field or a specific interaction region.

(b) Non-current assets

Revenue from contracts with customers

(i) Disaggregated revenue information (Continued)

Diagram illustrating a 3D coordinate system with axes labeled x , y , and z . The axes are represented by blue lines. A blue rectangular prism is shown in the first octant, with its edges labeled with 'u' and 'd' characters. The top face is labeled 'u' and 'd', the front face is labeled 'u' and 'd', and the right face is labeled 'u' and 'd'. The bottom face is labeled 'u' and 'd'. The left face is labeled 'u' and 'd'. The back face is labeled 'u' and 'd'. The prism is divided into smaller sections by horizontal lines.

(ii) Performance obligations

Sale of goods

Healthcare services, technology transfer services and consigned processing services

Technical consultancy services and maintenance services


d	d		u	u
d	d	u	u	u
d	d			

d


Response	Percentage
Yes	75%
No	25%

d		d	u	
d				
d		u	u	
d	u d	d	u	
d			d	
u		u	u	
			d	

d		
d (note 15)		



<hr/>	
<i>Executive directors</i> u	
u	
<hr/>	
<i>Non-executive directors</i> u u u	
u	
u	
<hr/>	
<i>Supervisors</i> u	
u	
<hr/>	
<i>Chief Executive</i> u	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
<i>Executive directors</i> u	
u	
<hr/>	
<i>Non-executive directors</i> u u u	
<hr/>	
<hr/>	
<i>Supervisors</i> u	
u	
<hr/>	
<i>Chief executive</i> u	
<hr/>	
<hr/>	
<hr/>	
<hr/>	
u u	d
u	d
d	u
u	d
d	u
d	u
u	u
u	u



31 December 2018

u	d	
u	u	
u	d	
	(note 37)	
	(note 38)	
	d	
u		
u	u	
	d	
u		

31 December 2018

Goodwill of Aohong Pharma (Continued)

[illegible]

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The letters are distributed in a seemingly random pattern across the grid.

Goodwill of Alma

Goodwill of Alma (Continued)

The diagram illustrates a complex network structure, likely representing a graph or a system of interconnected components. The nodes are labeled with letters 'u' and 'd', and the connections are represented by lines. The network is highly interconnected, with many nodes having multiple connections, suggesting a dense or highly connected system. The layout is somewhat irregular, with nodes distributed across the space and connected in a non-linear fashion. The overall structure appears to be a single, unified network rather than multiple separate components.

A 10x10 grid of 100 cells, each containing either a lowercase 'u' or a lowercase 'd'. The distribution is random, with approximately 45 'u's and 55 'd's.

Healthcare service (Continued)
Goodwill of Hengsheng Hospital (Continued)

u	u	d	u	u	u	u	d	d
u	d		d		u		d	
	u	d	u	u	d			
du	d		d	u	u	u	d	d
					u	d	u	d
d					u	d	u	
	u		d	d			u	d
	u	u	d					
					d			
	d							
ud	d		u	d	d	u	d	ud
	d	d		d		ud	d	d
u		d	u	u	d	u	u	d
		d		d				
u	d		u	d			d	du
		u	d		u			

<div> <div>u</div> <div>dd</div> <div>u u d</div> <div>(note 37)</div> </div>	
<div> <div>u d</div> <div>(note 38)</div> </div>	
<div> <div>u</div> <div>(note 7)</div> <div>u u d</div> <div>(note 37)</div> <div>u d</div> <div>(note 38)</div> </div>	
<div> <div>u d</div> </div>	
<div> <div>u</div> </div>	

d

u

d

d

u d d

d

d

u

u d d

d

d

u d d

d

u d d

d

d

u d d

d d u

u

d du
d du

d u

u

d

u d

d

d

d

u

u

u

u

d

u

d

u d

d

d

d	u	

U U U d

U U d d d d
U d d
U U

d d d # d d
U d 掛號網 # d U

U
d 復星康健融資租賃 上海 有限公司

U d d U U d
重藥控股股份有限公司 # d

U d 淮海醫院管理 徐州 有限公司 #

d d U
上海領健信息技術有限公司 #

d d# d d d d

d U d# d d d d

U U d d U U

U U d d U d U U d U U U U U

d d U U d d U U d U U d U U d U U d U U

The diagram illustrates two rows of musical notation on staves. The top row contains two measures of music, each with a blue rectangular block on the right side. The bottom row contains two measures of music, each with a blue rectangular block on the right side. The notation consists of notes and rests on a five-line staff.

[illegible]

<div> <div> <div>d</div> <div>d</div> </div> <div>u</div> </div> <div> <div>u</div> <div>d</div> <div>u</div> <div>d</div> </div> <div> <div>du</div> <div>d</div> <div>d</div> <div>d</div> <div>d</div> <div>du</div> </div>	
<div> <div>d</div> <div>d</div> </div>	
<div> <div>d</div> </div> <div> <div>d</div> <div>d</div> <div>u</div> <div>d</div> </div>	
<div> <div>u</div> <div>u</div> <div>d</div> </div> <div> <div>(note 37)</div> <div>d</div> <div>d</div> <div>d</div> <div>d</div> </div> <div> <div>du</div> <div>d</div> <div>d</div> <div>d</div> <div>d</div> <div>du</div> <div>d</div> </div>	
<div> <div>d</div> <div>d</div> </div>	

d d d d d		d	
		u u	
d			
d			
d		u d	
u d d d d			
du d			
u		d d d d	
		d	
d d u			

Annual Report 2018 187

1. 2019 年 12 月 31 日，公司应收账款余额为 1,234,567.89 元，较 2018 年 12 月 31 日增加 12.34%。主要系公司 2019 年销售规模扩大，应收账款相应增加所致。

2. 2019 年 12 月 31 日，公司预付款项余额为 567,890.12 元，较 2018 年 12 月 31 日减少 5.67%。主要系公司 2019 年预付账款到期，收到货物所致。

3. 2019 年 12 月 31 日，公司其他应收款余额为 345,678.90 元，较 2018 年 12 月 31 日增加 3.45%。主要系公司 2019 年其他应收款增加所致。

4. 2019 年 12 月 31 日，公司存货余额为 890,123.45 元，较 2018 年 12 月 31 日增加 8.90%。主要系公司 2019 年存货增加所致。

5. 2019 年 12 月 31 日，公司固定资产余额为 2,345,678.90 元，较 2018 年 12 月 31 日增加 2.34%。主要系公司 2019 年固定资产增加所致。

6. 2019 年 12 月 31 日，公司无形资产余额为 1,234,567.89 元，较 2018 年 12 月 31 日增加 1.23%。主要系公司 2019 年无形资产增加所致。

7. 2019 年 12 月 31 日，公司长期股权投资余额为 567,890.12 元，较 2018 年 12 月 31 日增加 5.67%。主要系公司 2019 年长期股权投资增加所致。

8. 2019 年 12 月 31 日，公司其他非流动资产余额为 345,678.90 元，较 2018 年 12 月 31 日增加 3.45%。主要系公司 2019 年其他非流动资产增加所致。

9. 2019 年 12 月 31 日，公司应付账款余额为 1,234,567.89 元，较 2018 年 12 月 31 日增加 12.34%。主要系公司 2019 年应付账款增加所致。

10. 2019 年 12 月 31 日，公司预收款项余额为 567,890.12 元，较 2018 年 12 月 31 日减少 5.67%。主要系公司 2019 年预收账款到期，收到货款所致。

11. 2019 年 12 月 31 日，公司其他应付款余额为 345,678.90 元，较 2018 年 12 月 31 日增加 3.45%。主要系公司 2019 年其他应付款增加所致。


12. 2019 年 12 月 31 日，公司应付债券余额为 890,123.45 元，较 2018 年 12 月 31 日增加 8.90%。主要系公司 2019 年应付债券增加所致。

13. 2019 年 12 月 31 日，公司长期负债余额为 2,345,678.90 元，较 2018 年 12 月 31 日增加 2.34%。主要系公司 2019 年长期负债增加所致。

14. 2019 年 12 月 31 日，公司所有者权益余额为 1,234,567.89 元，较 2018 年 12 月 31 日增加 1.23%。主要系公司 2019 年所有者权益增加所致。

1. 2019 年 12 月 31 日，公司应收账款余额为 1,234,567.89 元，较 2018 年 12 月 31 日增加 12.34%。主要系公司 2019 年销售规模扩大，应收账款相应增加所致。		

31 December 2018



31 December 2018

d

d d

d

d

d

d

d

u d d

u

d

d

u d u

u u

u

u d

d u u

d

u u

[illegible]

Notes:

[illegible]

	%	u
u		
u u d		
u d (note (a))		
u		
u u d		
u d (note (a))		
d u u d		
u u d		
u d (note (a))		
d (note (b))		

d d d d d d u	
d d d u	

	Notes	
d u (note 30)		
d u (note 30)		

Notes:

The diagram illustrates a 2D hexagonal lattice structure. A central 2x2 cluster of hexagons is highlighted in a darker blue, representing a specific region of interest. The lattice is bounded by thick blue horizontal lines at the top and bottom. Various labels (u, d, di, u) are placed near specific hexagons, indicating different types of sites or interactions.

u u d u d
d d u
d u d
u d u u u u d u d d u
u u u u u d d d u u u u d
d u d d d u d u u d u d
u u d d d u d u d u d
u d u u d u d u d u d
u d u u d u d u d u d

37.

u u d u d u u
u u d u u d u u d
d d u u d u d u d
d u d u d u d u d
u d u d u d u d u
u u u d u d u d u d u
u u d u d u d u d u d u d u
u u d u d u d u d u d u d u

u u u u d u d u u u u u
 u u d d u d d u u u u d u d
 u d u d d u d u d u d u d
 u d d d u d u d d d

Notes


d u
 d d
 u u
 d
 u
 d d
 d
 d d
 d d
 d u
 d
 d

d u

d u

d d d
 d

Annual Report 2018 203



u d d d

Note

<p>d d d u</p> <p>d d</p> <p>d</p> <p>u</p> <p>d d</p> <p>d d u</p> <p>d d</p> <p>d u</p>		
<p>u d u d d d</p> <p>d u d</p>		
<p>d d d</p>		
<p>d u d u d</p>		
<p>d d d u</p> <p>d d u d</p>		

u	
u u d	

[illegible]

Restricted A-share Incentive Scheme I (Continued)

《與績效考核相關管理辦法》

Restricted A-share Incentive Scheme II

Figure 1. The location of the study area in the north-east of Iran.

A scatter plot showing the relationship between the number of children and the number of adults in a household. The x-axis is labeled 'Number of children' and ranges from 0 to 10. The y-axis is labeled 'Number of adults' and ranges from 0 to 10. Data points are represented by 'u' for adults and 'd' for children. The plot shows a positive correlation, with most households having 1-3 children and 1-3 adults. There are a few outliers with 4 or 5 children and 1 adult.

Restricted A-share Incentive Scheme II (Continued)

u u d d u u d
d
du u d u u u u d

u	

d d u d u u u d
du

u	

dd d d u d

d u d d d d u d d u u u d u d d d	

As lessor

u	d	d	u	d	(notes 6, 8, 11 & 14)	
u				d	(notes 2 & 8)	
		d			d (notes 2 & 8)	
	u		d		d (notes 5 & 8)	
			u		d (notes 4 & 8)	
u	u	u	d		d (notes 1 & 8)	
		u		u		
(notes 2 & 8)						
					(notes 4 & 8)	
	u		d	d	u	d (notes 4, 8 & 9)

As lessee

u			d	d	u	d	(notes 6, 8, 11 & 15)
	d	u	d				
							d (notes 3, 8 & 11)
							(notes 3 & 8)
							(notes 3 & 8)

Management services

u d u d (notes 6, 8, 11 & 16)

Maximum daily outstanding balance of deposits in Fosun Finance

u u d (notes 10 & 11)

Loans to Fosun Kite Biological Technology Co., Ltd.

■ (notes 2&11)

du d d (notes 2&11)201Tn

u	u	■ (notes 10 & 11)	
u		■ (notes 2 & 11)	
u	u	■ (note 1)	

	■	u	■		■	u	■
			■				u
■	■		■		u	■	
■	u						

As lessor


	u	■	u	u	u	u	■
■		■					

u	■	u	(note 6)				
		u		■			
			(note 2)				
	u			■ (note 5)			
			■ (note 1)				
u	u	u	■		■ (note 1)		
		u	■ (note 4)				
	u	■ (note 9)					

As lessee

		u	■	u	u	u	■	u	■	■	■	u	■
■	u												

u			■ (note 2)				
	■	u	■				
		■ (note 3)					
u	■	u	(note 6)				



u

u

d

d

[illegible]

224 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

As at 31 December 2018

u u
(note 27)
u d d u
u
(note 21)

Handwriting practice sheet for the letter 'u'. The sheet is divided into two columns by a vertical line. Each column contains four sets of horizontal lines for writing practice. The letter 'u' is scattered throughout the sheet for tracing and writing practice. The letter 'u' is shown in various sizes and orientations, including lowercase 'u' and uppercase 'U'. Some 'u's are accompanied by arrows indicating the stroke direction. The sheet also includes the text '(note 21)' and '(note 27)' in the left column.

Liabilities measured at fair value:
As at 31 December 2018

Diagram illustrating a 2D lattice structure. The lattice is divided into two regions by a vertical line. The left region is white, and the right region is blue. The vertical line is labeled 'u' at the top and 'd' at the bottom. The lattice sites are represented by dots. The top row of the blue region contains four blue sites. The bottom row of the blue region contains four blue sites. The top row of the white region contains four white sites. The bottom row of the white region contains four white sites.

As at 31 December 2017

u d

u u u

u u

u u

u d

(note 34)


u u d u

A diagram of a 2D lattice with a blue vertical strip. The lattice is represented by a grid of points. A vertical strip of points is highlighted in blue, extending from the top to the bottom of the lattice. The strip is located in the center of the lattice. The lattice is bounded by horizontal lines at the top and bottom, and vertical lines on the left and right. The blue strip is a vertical column of points, with a small gap in the middle. The points are arranged in a regular grid pattern.

As at 31 December 2018

As at 31 December 2017

The diagram shows a 4x4 grid of cells. The top row consists of four grey cells, each containing a 'u'. The second row has a grey cell with 'u' at column 1, a grey cell with 'd' at column 2, and two blue cells at columns 3 and 4. The third row has a grey cell with 'u' at column 1, a grey cell with 'u' at column 2, and two blue cells at columns 3 and 4. The bottom row has a grey cell with 'u' at column 1, a grey cell with 'u' at column 2, a blue cell with 'd' at column 3, and a blue cell with 'd' at column 4.



u d u u u u u u u d
d u d u d d u u d
d d u d d u d u



u	d		d		d		d	d	d		d		u
u			d		d		u		d		du		dd
			d				d	u	u		dd		
d		u						d			dd		d
u		d	u		u			u	u	u			u
	u	d			d		d	d	d		d		
u					d		d			u	u		d
							d			u	u		
u	d			d	d		d						

Maximum exposure and year-end staging as at 31 December 2018


		d	u		d		u		u		d		u		d
		d	du		u					d	u	u	du		d
	d							d	d					u	
u		d			u			d		u		d			
u															

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

d	d														
			u	d	d										
				d											
		u													
	d														
			du												

	d	d			d				u		d				d
				d											
		u						u	d		d				
		du		d											
			d	u											
								d	d		d	u	u		

Annual Report 2018 233



	%	/	/	/
d				
u	u			
u	u			
	u	u		
	u	u		
u	u			
u	u			
u	u			
u	u	u		
u	u	u		
		u		
u	u			
u	u			
	u			u
	u			u
u	u			
u	u			
		u	u	
u				
u				

d

u
u u
u u
u
u u
u u

u u

ud d

	%
(note 31)	
d u d d d (note 28)	
d	
u	
u d d	
	%

u d d d d d d d d d
u u u d d u d d u u u u u u
d d d d u u d d d d d d d d
u d d u u u u u u u u u u
u d d d d d d d d d d d d

u u u d d d d d d d d d
d d d d d d d d d d d d d
d d d d d d d d d d d d d
u u u u u u u u u u u u u
u u u u u u u u u u u u u

d d d d d d d d d d d d d
u u u u u u u u u u u u u
d d d d d d d d d d d d d
u u u u u u u u u u u u u

31 December 2018

u u d

du[illegible]

d d u d u d d


u u u u
 d d d d u
 d d d d
 u u
 d 安吉創新科技有限公司
 u u d 錦州奧鴻藥業有限責任公司
 u d
 u d u
 u u
 u d 新興 鐵嶺 藥業股份有限公司 d
 u u d 遼寧新興藥業股份有限公司 u d
 d
 du d 中航新興產業投資有限公司
 d 北京高地物業管理有限公司
 u u d u
 u
 d d d
 d 上海伯豪生物技術有限公司
 d 上海伯豪醫學檢驗所有限公司
 u d d
 d d u u d
 d d u
 d d u
 u d u u
 d u d u
 d u d
 監督管理局 u d
 u d 中國科學器材有限公司



u u d u d u u d u
 d u
 u u
 u 上海復星高科技 集團 有
 限公司 d u d u d u d u
 d u
 u
 u 復星控股有限公司 d u d u
 d d d
 u 上海復星醫院投資 集團 有限公
 司 u d u
 u 復星國際有限公司 d u d u
 d d d
 u 復星國際控股有限公司 d
 d u u d u d
 d
 u u d u
 u 復星領智 上海 醫藥科技有限
 公司 u d
 u 上海復星長征醫學科學有限公司
 u d
 u d u d d u d
 u 復星弘創 蘇州 醫藥科技有限公司 u d
 u d u d
 u 上海復星醫
 藥產業發展有限公司 u d
 u 上海復星平耀投資管理有限
 公司 u d
 u u 上海復拓生物科技發展有限公司
 u d
 du
 d d d u d
 d u u

u u d u d d u u d
 u d u u d u d u d
 u u d u d u d
 u u u d 岳陽廣濟醫院有限公司 u d
 u u u 桂林南藥股份有限公司 u d
 d d d u d d
 d d d u d
 d d d u d
 u u d 海圀 上海 國際貿易有限公司
 d d
 u d 黑龍江萬邦醫藥有限公司
 深圳恒生醫院 u d
 d d
 d u u
 u u
 u u
 u d 瀋陽紅旗製藥有限公司 u d
 u u d 湖南景仁醫療投資管理有限
 公司
 d d d d
 u u u d 直觀復星醫療器械技
 術 上海 有限公司
 u u u 北京建優成業汽車銷售有限公司
 u d d
 u 安徽濟民腫瘤醫院 u 民辦 非
 企業單位 u d

量富征信管理有限公司
 中華人民
 共和國國家藥品監督管理局
 《中華人民共和國公司法》
 《中華人民共和國企業所得稅法》
 《中華人民共和國證券法》
 謙達 天津 國際貿易有限公司



2

u u u

司 u u

d u

d

上海卓瑞綜合門診部有限公

u u

u

u u

d

d

d

u

